These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Prognostic value of right ventricular systolic function in cardiac amyloidosis. Bodez D; Ternacle J; Guellich A; Galat A; Lim P; Radu C; Guendouz S; Bergoend E; Couetil JP; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Deux JF; Mohty D; Damy T Amyloid; 2016 Sep; 23(3):158-167. PubMed ID: 27348696 [TBL] [Abstract][Full Text] [Related]
6. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. Rapezzi C; Quarta CC; Guidalotti PL; Pettinato C; Fanti S; Leone O; Ferlini A; Longhi S; Lorenzini M; Reggiani LB; Gagliardi C; Gallo P; Villani C; Salvi F JACC Cardiovasc Imaging; 2011 Jun; 4(6):659-70. PubMed ID: 21679902 [TBL] [Abstract][Full Text] [Related]
7. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis. Sperry BW; Vranian MN; Hachamovitch R; Joshi H; Ikram A; Phelan D; Hanna M J Am Heart Assoc; 2016 Mar; 5(3):e002877. PubMed ID: 27013539 [TBL] [Abstract][Full Text] [Related]
8. Cardiac amyloidosis: a practical approach to diagnosis and management. Kapoor P; Thenappan T; Singh E; Kumar S; Greipp PR Am J Med; 2011 Nov; 124(11):1006-15. PubMed ID: 22017778 [TBL] [Abstract][Full Text] [Related]
9. Comparison between (99m)Tc-diphosphonate imaging and MRI with late gadolinium enhancement in evaluating cardiac involvement in patients with transthyretin familial amyloid polyneuropathy. Minutoli F; Di Bella G; Mazzeo A; Donato R; Russo M; Scribano E; Baldari S AJR Am J Roentgenol; 2013 Mar; 200(3):W256-65. PubMed ID: 23436870 [TBL] [Abstract][Full Text] [Related]
10. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Bennani Smires Y; Victor G; Ribes D; Berry M; Cognet T; Méjean S; Huart A; Roussel M; Petermann A; Roncalli J; Carrié D; Rousseau H; Berry I; Chauveau D; Galinier M; Lairez O Int J Cardiovasc Imaging; 2016 Sep; 32(9):1403-1413. PubMed ID: 27240600 [TBL] [Abstract][Full Text] [Related]
12. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Rubin J; Maurer MS Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086 [TBL] [Abstract][Full Text] [Related]
13. Recent advances in the diagnosis and management of cardiac amyloidosis. Sher T; Gertz MA Future Cardiol; 2014 Jan; 10(1):131-46. PubMed ID: 24344669 [TBL] [Abstract][Full Text] [Related]
14. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308 [TBL] [Abstract][Full Text] [Related]
15. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Rapezzi C; Quarta CC; Obici L; Perfetto F; Longhi S; Salvi F; Biagini E; Lorenzini M; Grigioni F; Leone O; Cappelli F; Palladini G; Rimessi P; Ferlini A; Arpesella G; Pinna AD; Merlini G; Perlini S Eur Heart J; 2013 Feb; 34(7):520-8. PubMed ID: 22745357 [TBL] [Abstract][Full Text] [Related]
16. Amyloid cardiomyopathy. Kristen AV Herz; 2020 May; 45(3):267-271. PubMed ID: 32107564 [TBL] [Abstract][Full Text] [Related]
17. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. Buss SJ; Emami M; Mereles D; Korosoglou G; Kristen AV; Voss A; Schellberg D; Zugck C; Galuschky C; Giannitsis E; Hegenbart U; Ho AD; Katus HA; Schonland SO; Hardt SE J Am Coll Cardiol; 2012 Sep; 60(12):1067-76. PubMed ID: 22883634 [TBL] [Abstract][Full Text] [Related]
18. Amyloid diseases of the heart: current and future therapies. Dubrey SW; Comenzo RL QJM; 2012 Jul; 105(7):617-31. PubMed ID: 22223674 [TBL] [Abstract][Full Text] [Related]
19. [What should we know about cardiac amyloidosis? From clinical signs to treatment]. Földeák D; Nemes A; Kalapos A; Domsik P; Kormányos Á; Krenács L; Bagdi E; Borbényi Z Orv Hetil; 2017 Nov; 158(46):1811-1818. PubMed ID: 29135289 [TBL] [Abstract][Full Text] [Related]
20. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]